GUILFORD, Conn. / Mar 24, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference to be held on Thursday, April 6, 2023.
Patrick Schneider, Ph.D., Quantum-Si’s President and Chief Operating Officer, will participate in the panel discussion “How to Translate Insights from Proteomics and Advances in AI into Drug Discovery and Innovation?” at 10:30 AM ET.
Additionally, Jeff Hawkins, Quantum-Si’s Chief Executive Officer, and Dr. Schneider will participate in a fireside chat at 2:30 PM ET.
A link for live and archived webcasts of both events will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
| Last Trade: | US$1.38 |
| Daily Change: | 0.75 118.01 |
| Daily Volume: | 278,845,174 |
| Market Cap: | US$168.940M |
November 20, 2024 November 20, 2024 November 20, 2024 November 12, 2024 November 07, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
